TLRY - Tilray, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
104.00
-2.77 (-2.59%)
At close: 4:00PM EST

103.80 -0.20 (-0.19%)
After hours: 4:00PM EST

Stock chart is not supported by your current browser
Previous Close106.77
Open100.00
Bid103.26 x 800
Ask104.38 x 800
Day's Range99.39 - 111.69
52 Week Range20.10 - 300.00
Volume1,704,212
Avg. Volume8,318,773
Market Cap9.689B
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-0.43
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est140.00
Trade prices are not sourced from all markets
  • MarketWatch5 hours ago

    Cannabis stocks are a green spot in a sea of red after reversing early losses

    Cannabis stocks reversed their early losses Tuesday to trade mostly higher, shrugging off the rout in the broader market which was falling as investors continued to sell off technology and internet stocks. Canopy Growth Corp. led the gainers, adding 2.9% in midmorning trade. Canopy is viewed as one of the stronger players in the new sector, thanks to a $4 billion investment from drinks giant Constellation Brands Inc. . Cronos Corp. was up 3.1%. Tilray Inc. was up 1.8% and Aphria Inc. was up 1.4%. Aurora Cannabis Inc. was up 2.1%, and Green Organic Dutchman Holdings was up 4.1%. The ETFMG Alternative Harvest ETF was up 0.6% and the Horizons Mariujana Life Sciences ETF was up 1%. The S&P 500 was down 1.4% and the Dow Jones Industrial Average was down 1.7%.

  • Tilray’s November Price Target and Recommendation Update
    Market Realist5 hours ago

    Tilray’s November Price Target and Recommendation Update

    Tilray (TLRY), which reported its earnings on November 13, missed both top-line and bottom-line consensus estimates, which led to a correction in the stock. Despite the earnings miss, the company remained optimistic about the future of the cannabis sector. In its earnings call, the company’s CEO, Brendan Kennedy, stated, “the cannabis industry remains very robust.” Learn more at Tilray Says ‘Cannabis Industry Remains Very Robust.’

  • What Analysts Recommend for Aurora Cannabis in November
    Market Realist7 hours ago

    What Analysts Recommend for Aurora Cannabis in November

    Last week, Aurora Cannabis (ACB)(ACBFF) reported year-over-year revenue growth of 260% in its first quarter, which ended on September 2018. The overall revenue partially included sales from recreational cannabis. Consequently, the gross margin expanded year-over-year from 58% to 70% in the first quarter. Let’s look at how analysts’ price target and recommendations for the company have changed after the earnings.

  • ACCESSWIRE7 hours ago

    4 Marijuana Stocks That Could Test New Highs This week

    CORAL GABLES, FL / ACCESSWIRE / November 20,2018 / Marijuana stocks have seen investors flooding the market. Cannabis industry reports continue to support the idea that the marijuana industry could be set to see strong growth within the next decade. Grand View Research reports that the global legal marijuana market size was valued at USD 9.3 billion in 2016 and is expected to exhibit a CAGR of 34.6% during the forecast period.

  • Canada's Top 7 Marijuana Growers Lost Nearly $300 Million This Quarter
    Motley Fool7 hours ago

    Canada's Top 7 Marijuana Growers Lost Nearly $300 Million This Quarter

    The much-anticipated earnings season for pot stocks hasn't been pretty.

  • ACCESSWIRE7 hours ago

    Cannabis Stocks Set to Rebound with Broader Market

    HENDERSON, NV / ACCESSWIRE / November 20, 2018 / Despite strong sales numbers across the cannabis industry, stocks in the sector have had rough go of it recently. This is most likely due to the overall ...

  • Trulieve Surpassed Analysts’ Q3 Revenue Estimates
    Market Realist8 hours ago

    Trulieve Surpassed Analysts’ Q3 Revenue Estimates

    The company reported revenues of $28.3 million during the third quarter of 2018 as compared to Wall Street analyst estimates of $26.6 million (or 35.1 million Canadian dollars) during the quarter. The below chart compares revenues for Trulieve since the third quarter of 2017. The Horizons Marijuana Life Sciences Index ETF (HMMJ) holds 11.8% of its total investments in Tilray (TLRY), 0.5% in WeedMD (WMD) (WDDMF), and 1.0% in Vivo Cannabis (VVCIF).

  • Marijuana Earnings Wrap-Up: Cannabis Stock Winners and Losers
    Motley Foolyesterday

    Marijuana Earnings Wrap-Up: Cannabis Stock Winners and Losers

    Investors didn't get the big pops they'd hoped to see.

  • Top and Flop ETFs of Last Week
    Zacksyesterday

    Top and Flop ETFs of Last Week

    Inside the winning and losing ETFs of the last week.

  • Can These 3 Pummeled Pot Stocks Recover?
    Motley Foolyesterday

    Can These 3 Pummeled Pot Stocks Recover?

    Replacing billions lost in recent weeks won't be easy for these Canadian cannabis producers.

  • MedMen’s Valuation versus Its Peers’
    Market Realistyesterday

    MedMen’s Valuation versus Its Peers’

    MedMen Enterprises (MMNFF) holds 19 licensed cannabis facilities for cultivation, manufacturing, and marketing cannabis as a consumer product. This article compares MedMen’s (MMNFF) valuation with its peers’, including Tilray (TLRY), CannaRoyalty (OH), and Maricann (MRRCF).

  • Cannabis Stocks Ended Last Week in Negative Territory
    Market Realistyesterday

    Cannabis Stocks Ended Last Week in Negative Territory

    The cannabis sector ended in negative territory last week. The Horizons Marijuana Life Sciences ETF (HMMJ) fell ~6.2%, and the ETFMG Alternative Harvest ETF (MJ) fell 5.8% during the period. Most cannabis stocks also ended in the negative territory.

  • MedMen’s Territory Expansion: The Recent Agreements
    Market Realistyesterday

    MedMen’s Territory Expansion: The Recent Agreements

    MedMen (MMNFF) has entered into agreements with different companies to expand its footprint. We outline a few of the recent agreements below.

  • ACCESSWIREyesterday

    4 Marijuana Stocks To Watch During Thanksgiving Week

    / This month marijuana stocks have been very active. As of November 7, US Attorney General Jeff Sessions is out and an interim AG is in. This all occurred following Canada’s full legalization of recreational and medicinal cannabis.

  • Best Big Marijuana Stock: Aurora Cannabis, Canopy Growth, or Tilray?
    Motley Fool2 days ago

    Best Big Marijuana Stock: Aurora Cannabis, Canopy Growth, or Tilray?

    They're the biggest. But which is the best?

  • 4 Prominent Marijuana Earnings Season Trends
    Motley Fool3 days ago

    4 Prominent Marijuana Earnings Season Trends

    Surprise! Pot stock operating results actually matter now.

  • 2 Reasons Pot Stocks Could Plunge in January
    Motley Fool3 days ago

    2 Reasons Pot Stocks Could Plunge in January

    It may be a buzzkill beginning to the New Year.

  • 3 Bear-Busting Stocks to Buy, Including Tilray
    InvestorPlace4 days ago

    3 Bear-Busting Stocks to Buy, Including Tilray

    The good news is — if you’re an investor that desires price volatility working for you rather than against you — Under Armour (NYSE:UAA), Chipotle (NYSE:CMG) and Tilray (NASDAQ:TLRY) are bear-busting stocks to buy today. Toss in decent, but not over-the-top short interest to help fuel the upside and the peace of mind that comes with owning brand recognition and a large-cap company—and the case for UAA, CMG and TLRY only grows stronger. Click to Enlarge The first of our large-cap stocks to buy is Under Armour.

  • Trulieve to Announce Q3 Earnings on November 19!
    Market Realist4 days ago

    Trulieve to Announce Q3 Earnings on November 19!

    Trulieve Cannabis Corp (TCNNF) is a licensed medical cannabis company set to release its Q3 2018 earnings on November 19 at 10:00 AM ET. Analysts expect Trulieve to report revenues of 35.1 million Canadian dollars for the third quarter of 2018. Trulieve is a vertically integrated cannabis company involved in the cultivation, production, and commercialization of cannabis products in the State of Florida.

  • Why Citron’s Andrew Left Is Shorting Cannabis Stocks
    Market Realist4 days ago

    Why Citron’s Andrew Left Is Shorting Cannabis Stocks

    Cannabis stocks have made several investors wary because of their high level of volatility. Earlier this week, some of the companies that reported earnings such as Canopy Growth (WEED), Tilray (TLRY), and Aurora Cannabis (ACB) (ACBFF) missed analysts’ estimates by a large margin, and the stocks got hammered. In an interview with CNBC, Andrew Left of Citron Research was largely pessimistic on the Canadian cannabis industry and expects that cannabis stocks will fall in the near term.

  • Tilray's Q3 Report Clearly Shows That It's Not Worth $10 Billion
    Motley Fool4 days ago

    Tilray's Q3 Report Clearly Shows That It's Not Worth $10 Billion

    This high-flying marijuana stock's operating results raise a number of red flags.

  • Why Tilray's Still Up Over 400% in 2018 to Date
    Motley Fool4 days ago

    Why Tilray's Still Up Over 400% in 2018 to Date

    Despite a big swoon, the recent cannabis IPO still has strong believers.

  • Jim Cramer’s Recommendations in the Cannabis Industry
    Market Realist4 days ago

    Jim Cramer’s Recommendations in the Cannabis Industry

    On November 15, the widely followed host of Mad Money on CNBC, Jim Cramer, gave his opinions on the cannabis industry. Cramer pointed investors to Canopy Growth (WEED) (CGC), the Canadian cannabis (HMMJ) giant, because of its backing from Constellation Brands as a result of the latter’s $4 billion investment.

  • Which Marijuana Stock Won Earnings Week -- Aurora Cannabis, Canopy Growth, Cronos Group, or Tilray?
    Motley Fool4 days ago

    Which Marijuana Stock Won Earnings Week -- Aurora Cannabis, Canopy Growth, Cronos Group, or Tilray?

    There was a flurry of earnings releases this week from leaders of the Canadian cannabis industry. Here are the winners and losers.

  • TheStreet.com5 days ago

    Putting the Markets in Focus: Cramer's 'Mad Money' Recap (Thursday 11/15/18)

    The big financial institutions are negative right now and that means any positive light is going to be bent into negative light, Jim Cramer told his Mad Money viewers on Thursday evening. Right now, all the talk is about "late cycle," as in, we're in the late stage of the economic cycle. The economy can handle the initial rate hikes from the Federal Reserve, because rates were so low to begin with, Cramer reasoned.